Patents Assigned to Hopital-Sainte-Justine
  • Publication number: 20140113313
    Abstract: A method for diagnosing an increased risk for developing adolescent idiopathic scoliosis (AIS) in a human subject, comprising detecting the presence or absence of at least one impairment in melatonin-signaling pathway in a cell sample of the subject in the presence and in the absence of a known melatonin-signaling pathway agonist, wherein the cell sample is selected from the group consisting of blood cell sample, osteoblast cell sample, osteoclast cell sample and myoblast cell sample, and wherein the presence of the at least one impairment in the melatonin-signaling pathway indicates that the subject possesses an increased risk for developing AIS.
    Type: Application
    Filed: December 30, 2013
    Publication date: April 24, 2014
    Applicant: HOPITAL SAINTE-JUSTINE
    Inventor: ALAIN MOREAU
  • Patent number: 8652791
    Abstract: A method of classifying a human subject having adolescent idiopathic scoliosis (AIS) comprising: providing a cell sample isolated from the subject; detecting an impairment in melatonin-signaling pathway in the sample in the presence and in the absence of a known melatonin-signaling pathway agonist, whereby the results of the detecting step enables the classification of the subject having AIS in one AIS subgroup; and a method of screening for a compound useful in the treatment of a disease characterized by a dysfunctional melatonin-signaling pathway, said method comprising the steps of contacting a candidate compound with at least one cell expressing at least one melatonin-signaling pathway impairment, wherein the candidate compound is selected if said melatonin-signaling pathway impairment is reduced in the presence of the candidate compound as compared to that in the absence thereof.
    Type: Grant
    Filed: December 24, 2012
    Date of Patent: February 18, 2014
    Assignee: Hôpital Sainte-Justine
    Inventor: Alain Moreau
  • Publication number: 20130115615
    Abstract: A method of classifying a human subject having adolescent idiopathic scoliosis (AIS) comprising: providing a cell sample isolated from the subject; detecting an impairment in melatonin-signaling pathway in the sample in the presence and in the absence of a known melatonin-signaling pathway agonist, whereby the results of the detecting step enables the classification of the subject having AIS in one AIS subgroup; and a method of screening for a compound useful in the treatment of a disease characterized by a dysfunctional melatonin-signaling pathway, said method comprising the steps of contacting a candidate compound with at least one cell expressing at least one melatonin-signaling pathway impairment, wherein the candidate compound is selected if said melatonin-signaling pathway impairment is reduced in the presence of the candidate compound as compared to that in the absence thereof.
    Type: Application
    Filed: December 24, 2012
    Publication date: May 9, 2013
    Applicant: HOPITAL SAINTE-JUSTINE
    Inventor: Hospital Sainte-Justine
  • Publication number: 20120196878
    Abstract: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.
    Type: Application
    Filed: August 30, 2011
    Publication date: August 2, 2012
    Applicant: Hôpital-Sainte-Justine
    Inventors: Ernest G. Seidman, Yves Théorêt
  • Publication number: 20120009600
    Abstract: A method for diagnosing an increased risk for developing adolescent idiopathic scoliosis (AIS) in a human subject, comprising detecting the presence or absence of at least one impairment in melatonin-signaling pathway in a cell sample of the subject in the presence and in the absence of a known melatonin-signaling pathway agonist, wherein the cell sample is selected from the group consisting of blood cell sample, osteoblast cell sample, osteoclast cell sample and myoblast cell sample, and wherein the presence of the at least one impairment in the melatonin-signaling pathway indicates that the subject possesses an increased risk for developing AIS.
    Type: Application
    Filed: June 21, 2011
    Publication date: January 12, 2012
    Applicant: HOPITAL SAINTE-JUSTINE
    Inventor: ALAIN MOREAU
  • Publication number: 20110256582
    Abstract: A method of classifying a human subject having adolescent idiopathic scoliosis (AIS) comprising: providing a cell sample isolated from the subject; detecting an impairment in melatonin-signaling pathway in the sample in the presence and in the absence of a known melatonin-signaling pathway agonist, whereby the results of the detecting step enables the classification of the subject having AIS in one AIS subgroup; and a method of screening for a compound useful in the treatment of a disease characterized by a dysfunctional melatonin-signaling pathway, said method comprising the steps of contacting a candidate compound with at least one cell expressing at least one melatonin-signaling pathway impairment, wherein the candidate compound is selected if said melatonin-signaling pathway impairment is reduced in the presence of the candidate compound as compared to that in the absence thereof.
    Type: Application
    Filed: June 21, 2011
    Publication date: October 20, 2011
    Applicant: HOPITAL SAINTE-JUSTINE
    Inventor: ALAIN MOREAU
  • Patent number: 8030293
    Abstract: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: October 4, 2011
    Assignee: Hopital-Sainte-Justine
    Inventors: Ernest G. Seidman, Yves Theoret
  • Patent number: 7989175
    Abstract: A method for classifying human subjects having adolescent idiopathic scoliosis (AIS) into AIS subgroups, comprising detecting an impairment in the melatonin-signaling pathway in a cell sample from the subject, wherein the impairment is detected by an accumulation of cyclic adenosine 5?-monophosphate (cAMP) in the cell sample as compared to a control sample in the presence of a known melatonin-signaling pathway agonist, wherein the results of the detection step enable the classification of the subject having AIS into an AIS subgroup.
    Type: Grant
    Filed: September 11, 2008
    Date of Patent: August 2, 2011
    Assignee: Hôpital Sainte-Justine
    Inventor: Alain Moreau
  • Publication number: 20100029692
    Abstract: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.
    Type: Application
    Filed: August 4, 2009
    Publication date: February 4, 2010
    Applicant: Hopital-Sainte-Justine
    Inventors: Ernest G. Seidman, Yves Théorêt
  • Patent number: 7625876
    Abstract: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: December 1, 2009
    Assignee: Hopital-Sainte-Justine
    Inventors: Ernest G. Seidman, Yves Theoret
  • Patent number: 7442763
    Abstract: The present invention relates to a composition of matter comprising novel prostaglandin E2 receptor antagonists, and their use in treatments for regulating the fluid filtration in the kidney, preventing bone mineral loss in osteoporosis and dental disease and additionally, closure of ductus arteriosus (DA) in premature infants or fetal animals. Additionally, the compositions include linear peptides, peptide analogs, and peptidomimetics.
    Type: Grant
    Filed: June 4, 2002
    Date of Patent: October 28, 2008
    Assignee: Hopital Sainte-Justine
    Inventors: Krishna G. Peri, Sylvain Chemtob
  • Patent number: 7429570
    Abstract: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.
    Type: Grant
    Filed: March 21, 2007
    Date of Patent: September 30, 2008
    Assignee: Hopital Sainte-Justine
    Inventors: Ernest G. Seidman, Yves Theoret
  • Patent number: 7425546
    Abstract: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.
    Type: Grant
    Filed: March 22, 2007
    Date of Patent: September 16, 2008
    Assignee: Hopital Sainte-Justine
    Inventors: Ernest G. Seidman, Yves Theoret
  • Publication number: 20080166750
    Abstract: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.
    Type: Application
    Filed: August 20, 2007
    Publication date: July 10, 2008
    Applicant: Hopital Sainte-Justine
    Inventors: Ernest G. Seidman, Yves Theoret
  • Patent number: 7326694
    Abstract: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.
    Type: Grant
    Filed: May 26, 2006
    Date of Patent: February 5, 2008
    Assignee: Hopital Sainte-Justine
    Inventors: Ernest G. Seidman, Yves Theoret
  • Publication number: 20070197554
    Abstract: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.
    Type: Application
    Filed: March 22, 2007
    Publication date: August 23, 2007
    Applicant: Hopital Sainte-Justine
    Inventors: Ernest Seidman, Yves Theoret
  • Publication number: 20070197461
    Abstract: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.
    Type: Application
    Filed: March 21, 2007
    Publication date: August 23, 2007
    Applicant: Hopital Sainte-Justine
    Inventors: Ernest Seidman, Yves Theoret
  • Publication number: 20060205084
    Abstract: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.
    Type: Application
    Filed: May 26, 2006
    Publication date: September 14, 2006
    Applicant: Hôpital Sainte-Justine
    Inventors: Ernest Seidman, Yves Theoret
  • Patent number: 7105497
    Abstract: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.
    Type: Grant
    Filed: June 14, 2005
    Date of Patent: September 12, 2006
    Assignee: Hôpital Sainte-Justine
    Inventors: Ernest G. Seidman, Yves Theoret
  • Publication number: 20050234078
    Abstract: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.
    Type: Application
    Filed: June 14, 2005
    Publication date: October 20, 2005
    Applicant: Hopital Sainte-Justine
    Inventors: Ernest Seidman, Yves Theoret